Short answer
Orthofix Medical Inc. (OFIX) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 7.01 (Regulation FD Disclosure). Q2 results for quarter ended June 30, 2026 announced August 5, 2026, with detailed figures in Exhibit 99.1.
Orthofix Medical Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 results for quarter ended June 30, 2026 announced August 5, 2026, with detailed figures in Exhibit 99.1
- Management emphasizes adjusted EBITDA, excluding merger, M6, restructuring, litigation, acquisition and employee transition costs
- M6 product-line losses excluded from ongoing performance metrics, reflecting Orthofix’s exit from that business
- Investors should compare GAAP results with adjusted measures, as exclusions include costs that may affect cash flow
- Normalized long-term tax rate assumption set at 28% for 2025 and 2026 adjusted results
Item 7.01 · Regulation FD Disclosure
- Investor relations presentation planned for use with investors and analysts through fiscal 2026
- Exhibit 99.2 likely contains the company’s current investor messaging and key performance materials
Item EX-99.1 · Exhibit EX-99.1
- Q2 net sales $210.9M, up 3.8% reported and 4.7% pro forma constant currency, supporting improved operating momentum
- Global Limb Reconstruction grew 13.2%, while Global Spine increased 3.5% pro forma, offsetting weaker portfolio areas
- Adjusted EBITDA $20.1M, down from $20.6M; margin declined to 9.6% from 10.3%, signaling limited near-term operating leverage
- Net loss widened to $15.8M from $14.1M, with cash flow pressured by $23.8M operating outflows and $47.1M free-cash-flow burn
- Full-year guidance raised to $845M–$855M sales and $95M–$98M adjusted EBITDA following Medicare reimbursement restoration
Item EX-99.2 · Exhibit EX-99.2
- Q2 2026 net sales $210.9M, up 5% YoY pro forma constant currency
- Adjusted EBITDA $20.1M, 10% margin, versus $20.6M in Q2 2025
- Adjusted gross margin 71.7%, down from 72.7% due to unfavorable geographic mix
- Global spine fixation grew 10% and limb reconstruction 11%, supporting commercial momentum
- 2026 guidance: $845M–$855M net sales and $95M–$98M adjusted EBITDA, pro forma constant currency
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Orthofix Medical Inc. 8-K filings
Get the next OFIX 8-K as it lands
Follow OFIX for push alerts, or ask the research agent what this filing means.